Market Place
Sourcing Support
BiomX Reports Q3 2024 Financial Results & Updates
14 Nov 2024 //
GLOBENEWSWIRE
BiomX to Host Q3 2024 Financial Results Call & Webcast
12 Nov 2024 //
GLOBENEWSWIRE
BiomX Announces a Mandatory Unit Separation
15 Oct 2024 //
GLOBENEWSWIRE
BiomX To Update On BX004 Trial At CF Conference
18 Sep 2024 //
GLOBENEWSWIRE
BiomX To Present At H.C. Wainwright Conference
04 Sep 2024 //
GLOBENEWSWIRE
BiomX to Present Positive BX004 Phase 1b/2a Data at ERS Congress 2024
03 Sep 2024 //
GLOBENEWSWIRE
UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split
16 Aug 2024 //
GLOBENEWSWIRE
BiomX Inc. Announces 1-for-10 Reverse Stock Split
15 Aug 2024 //
GLOBENEWSWIRE
BiomX Reports Q2 2024 Financials, Business, And Program Updates
15 Aug 2024 //
GLOBENEWSWIRE
BiomX To Host Q2 2024 Results Conference Call On August 15, 2024
08 Aug 2024 //
GLOBENEWSWIRE
BiomX Announces NYSE American Acceptance Of Compliance Plan
29 Jul 2024 //
GLOBENEWSWIRE
BiomX Stockholders Approve Series X Preferred Stock Conversion
10 Jul 2024 //
GLOBENEWSWIRE
BiomX Receives NYSE Deficiency Notice
30 May 2024 //
GLOBENEWSWIRE
BiomX To Present BX004 Data At European CF And ASM Microbe Conferences
30 May 2024 //
GLOBENEWSWIRE
BiomX Reports Q1 2024 Results, Program Updates
21 May 2024 //
GLOBENEWSWIRE
BiomX Announces the Appointment of Susan Blum to its Board of Directors
18 Apr 2024 //
GLOBENEWSWIRE
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
04 Apr 2024 //
BIOSPACE
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results
03 Apr 2024 //
GLOBENEWSWIRE
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics
18 Mar 2024 //
GLOBENEWSWIRE
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics
06 Mar 2024 //
GLOBENEWSWIRE
BiomX acquires fellow bacteria-killing virus company APT
06 Mar 2024 //
FIERCE BIOTECH
BiomX Receives Orphan Drug Designation from the FDA for BX004
04 Jan 2024 //
GLOBENEWSWIRE
BiomX to Host Virtual Key Opinion Leader (KOL) Event
30 Nov 2023 //
GLOBENEWSWIRE
BiomX Announces Positive Results fromPhase 1b/2a Trial Evaluating BX004
29 Nov 2023 //
GLOBENEWSWIRE
BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update
14 Nov 2023 //
GLOBENEWSWIRE
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004
27 Oct 2023 //
GLOBENEWSWIRE
BiomX Announces Completion of Patient Dosing in Ph 1b/2a Study Evaluating BX004
04 Oct 2023 //
GLOBENEWSWIRE
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004
07 Sep 2023 //
GLOBENEWSWIRE
BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update
09 Aug 2023 //
GLOBENEWSWIRE
BiomX to Host Second Quarter 2023 Financial Results Conference
02 Aug 2023 //
GLOBENEWSWIRE
BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004
31 May 2023 //
GLOBENEWSWIRE
BiomX Reports First Quarter 2023 Financial Results and Provides Business Update
15 May 2023 //
GLOBENEWSWIRE
BiomX Appoints Jason M. Marks and Michael E. Dambach to Board of Directors
12 May 2023 //
GLOBENEWSWIRE
BiomX to Host 1Q 2023 FYR Conference Call and Webcast on May 15th, 2023
08 May 2023 //
GLOBENEWSWIRE
BiomX Announces Second Closing of $7.5 Million Private Placement
05 May 2023 //
GLOBENEWSWIRE
BiomX Reports Fourth Quarter and Full Year 2022 Financial Results
29 Mar 2023 //
GLOBENEWSWIRE
BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference
27 Mar 2023 //
GLOBENEWSWIRE
BiomX Announces Results from Part 1 of the Phase 1b/2a Study Evaluating BX004
22 Feb 2023 //
GLOBENEWSWIRE
BiomX Announces $7.5 Million Private Placement
22 Feb 2023 //
GLOBENEWSWIRE
BiomX To Present at Annual Investor Conference on Bacteriophage
29 Nov 2022 //
GLOBENEWSWIRE
BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update
09 Nov 2022 //
GLOBENEWSWIRE
BiomX to Host Third Quarter 2022 Financial Results Conference Call
02 Nov 2022 //
GLOBENEWSWIRE
BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference
11 Sep 2022 //
BUSINESSWIRE
BiomX To Report First Part Of CF Trial Data In September
02 Sep 2022 //
NASDAQ
BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update
10 Aug 2022 //
BUSINESS WIRE
BiomX to Host Second Quarter 2022 Financial Results Conference Call
07 Aug 2022 //
BUSINESSWIRE
BiomX to Publish Cell of Research Demonstrating Proof-of-Concept Assessment
04 Aug 2022 //
BUSINESSWIRE
BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange
06 Jul 2022 //
BUSINESSWIRE
BI and BiomX Collaborate to Discover IBD Microbiome Biomarkers
28 Jun 2022 //
BUSINESSWIRE
BiomX Begins Dosing in PIb/IIa Study of BX004 for Chronic Respiratory Infections
27 Jun 2022 //
BUSINESSWIRE
BiomX Announces Corporate Restructuring
24 May 2022 //
BUSINESSWIRE
BiomX Announces Publication in the Journal, Bioinformatics
20 May 2022 //
BUSINESSWIRE
BiomX Reports First Quarter 2022 Financial Results and Provides Business Update
11 May 2022 //
BUSINESSWIRE
BiomX to Host First Quarter 2022 Financial Results Conference Call
05 May 2022 //
BUSINESSWIRE
BiomX Reports Fourth Quarter and Full Year 2021 Financial Results
30 Mar 2022 //
BUSINESSWIRE
BiomX to Host Q4 and Full Year 2021 Financial Results
23 Mar 2022 //
BUSINESSWIRE
BiomX Announces Therapeutics Development Award of up to $5M
04 Jan 2022 //
BUSINESSWIRE
CF Foundation Awards Up to $5 Million to BiomX for Potential Phage Therapy
04 Jan 2022 //
BUSINESSWIRE
